Techonomy and Aon recently published an article featuring Aon’s innovative Intellectual Property (IP)-based lending model, including a case study with BrainScope, the only Food and Drug Administration (FDA)-cleared non-invasive medical device that objectively assess head injured patients for both brain bleeds and concussions at point of care.

According to a report from Ocean Tomo, intangible assets account for 90 percent of the value of S&P 500, equivalent to over $20 trillion. According to Lewis Lee, Aon’s head of Intellectual Property Solutions, “If data is the new oil, IP is the new gold.” Aon’s solution, which is “developing the ability to measure IP at scale” in Lee’s words, is solving the challenge of putting a cash value on IP. “Our platform aggregates not only intellectual property data but also financial data. We look at risk data, we look at litigation data, we look at licensing data and then we use a series of algorithms to understand those in a material way.”

 In 2021, BrainScope and Aon announced a $35 million IP-backed lending arrangement, which provided BrainScope with the resources to expand its reach to hospitals and provide more doctors with rapid, objective insights.

To read more, you can access the article here. Check out the other articles in the series with Techonomy, covering innovation in unexpected places and apprenticeships.